Please see 2nd reference. It lists a 2024 publicat
Post# of 145747
2. Adams DL, Raghavakaimal A, Tang CM, et al. Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (leronlimab): a pooled analysis of three clinical trials in patients with mTNBC. J Clin Oncol. 2024;40(suppl 16). doi:10.1200/JCO.2022.40.16_suppl
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)